Compare 3M Company (MMM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Sanofi SA — how do they compare? 3M Company trades at $159.96 (market cap $84.36B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: 3M Company and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Sanofi SA for 94 Days on average.
| MMM | SNY | |
|---|---|---|
Market Cap | $84.36B | $95.18B |
Volume | 2,325,301 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $183.79 | $52.34 |
52-Week Low | $141.10 | $39.51 |
Typical Hold Time | 169 Days | 94 Days |
Enterprise Value | $93.58B | $114.48B |
Dividend Yield | 1.91% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $163.57, up 0.89% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $2.40 EPS versus $2.25 expected, and raised full-year guidance. Revenue for 2025 was $24.95 billion with a net income margin of 11.9%, though profitability has moderated from prior years. Analysts maintain a consensus price target of $191.00, implying significant upside, with 48% recommending Buy.
The outlook for 3M is cautiously optimistic, driven by operational improvements and growth in industrial and electronics segments, but risks include high debt levels, weak consumer demand, and ongoing litigation costs. The stock's valuation at a P/E of 29.06 appears elevated relative to historical norms, requiring sustained earnings growth to justify further gains.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
